| Literature DB >> 35091954 |
Naseeba Parveen1, Shamik Chowdhury1, Sudha Goel2,3.
Abstract
Chlorinated disinfectants are widely used in hospitals, COVID-19 quarantine facilities, households, institutes, and public areas to combat the spread of the novel coronavirus as they are effective against viruses on various surfaces. Medical facilities have enhanced their routine disinfection of indoors, premises, and in-house sewage. Besides questioning the efficiency of these compounds in combating coronavirus, the impacts of these excessive disinfection efforts have not been discussed anywhere. The impacts of chlorine-based disinfectants on both environment and human health are reviewed in this paper. Chlorine in molecular and in compound forms is known to pose many health hazards. Hypochlorite addition to soil can increase chlorine/chloride concentration, which can be fatal to plant species if exposed. When chlorine compounds reach the sewer/drainage system and are exposed to aqueous media such as wastewater, many disinfection by-products (DBPs) can be formed depending on the concentrations of natural organic matter, inorganics, and anthropogenic pollutants present. Chlorination of hospital wastewater can also produce toxic drug-derived disinfection by-products. Many DBPs are carcinogenic to humans, and some of them are cytotoxic, genotoxic, and mutagenic. DBPs can be harmful to the flora and fauna of the receiving water body and may have adverse effects on microorganisms and plankton present in these ecosystems.Entities:
Keywords: Chlorine; Ecotoxicity; Environmental disinfection; Hospital wastewater; Human health impacts; Natural organic matter; Surface water quality; Trihalomethanes
Year: 2022 PMID: 35091954 PMCID: PMC8799444 DOI: 10.1007/s11356-021-18316-2
Source DB: PubMed Journal: Environ Sci Pollut Res Int ISSN: 0944-1344 Impact factor: 4.223
Fig. 1Countries that have opted for large-scale environmental disinfection practices (Map is prepared based on media reports)
Usage trends, ill effects, and risks of disinfectants observed during COVID-19
| Location | Assessment method | Usage trend/ill effects/risks/other observations about disinfectants | References |
|---|---|---|---|
| China | Questionnaire survey of general population ( | Out of 3667 respondents, 99.5% chose their disinfectant based on the disinfecting power of the chemical while only 12.3% considered environmental impact as a factor while choosing. Use of CBDs for household and environmental cleaning increased from 3.6 to 65.9% since COVID-19 outbreak; 81.3% tend to throw the unused disinfectants along with garbage, and 15.1% either flushed it through toilet/sink. | (Guo et al. |
| Iran | Questionnaire survey of general population ( | Approximately 77.9% of responders sanitized their hands at an average frequency of 10.74 times a day using either alcohol solutions (51% respondents) or sodium hypochlorite bleach (4.8% respondents). Bleach was preferred by low-income people for hand sanitizing since alcohol was costlier; 57.3% preferred bleach for surface disinfection. About 41.1% of respondent faced health issues such as skin dryness, skin itching, coughing, obsession, eye irritation, breath shortness, and headache while using disinfectants. | (Dindarloo et al. |
| Turkey | Questionnaire survey of general population ( | The amount of hand sanitizer, soap, and bleach increased around 92.7%, 87.4%, and 70.4%, respectively in the post-COVID-19 period. About 46.9% faced at least one health problem that they relate to the disinfectant use. The major health issue was on skin (itching/redness/scaling) followed by respiratory problems (shortness of breath/wheezing/burning in the chest, and asthma attack), and poisoning through skin or inhalation. | (Koksoy Vayisoglu and Oncu |
| Morocco | Chemical risk assessment and health survey ( | One hundred percent of survey participants used alcohol-based sanitizers, and about 60% used bleach as well. Alcohol-based sanitizers caused dermatological problems to 47% and psychological discomfort such as fear and stress to 10.5% of the population. The group that used CBDs experienced respiratory issues, dermatological problems, dizziness, memory problems, eye problems, psychological discomfort, and other health issues. | (Rachidi et al. |
| China | Ecotoxicity assessment on freshwater phytoplankton community | Phytoplankton | (Cui et al. |
| China | Bacterial analysis of MRSAa infection in a hospital. | A sharp increase in MRSA detection compared to 4 years pre-COVID-19 was observed in a mental health facility for elders in China. The samples collected from staff hands and environment showed an increase from 2.3% in 2019 before COVID-19 outbreak to 20.6% in 2020. Further, MRSA detection was found to increase with concentration and frequency of disinfectant. A reduction in chlorine application from 1000 to 500 mg/L showed significant reduction in the MRSA detection. | (Yang et al. |
| China | Occurrence of DBPs and pharmaceuticals in aquatic environment | Grab samples of effluent discharges collected after 2 weeks, 3 months, and 8 months showed comparatively similar concentrations (55.9 µg/L, 74 µg/L, and 57 µg/L, respectively) of 21 DBPs. However, the presence of pharmaceutical products, especially the ones used for COVID-19 treatments, was seen to be increasing. | (Z. Zhang et al. |
| China | Air sample analysis and health risk assessment | Air samples collected from 40 places before and 30 min after CBDs spraying showed at least 1.6 times higher concentrations of DBPs in the samples collected after spraying of CBDs. This shows that even in the air, there is DBP formation additional to that of aquatic environments. Chloroform was the most abundant DBP in the air. The median concentration of all DBPs was 34.1 µg/m3, 2.8 µg/m3, and 1.0 µg/m3 for hypochlorite spray doses of 100–200 mg/m3, 3–20 mg/m3, and 0 mg/m3, respectively. The health risk assessment showed a hazard index value of 0.5 (1 being the threshold for non-cancerous risks) for children indicating that this group may face inhalation-related risks. | (Lou et al. |
| China | DBP occurrence study | Water samples of rivers and lakes from Wuhan collected during COVID-19 pandemic contained THMs (2.2 µg/L), HANs (0.02 µg/L), and N-nitrosamines (60.8 ng/L). Prior to the pandemic outbreak, the DBPs concentration in Chinese surface waters was steady and at low levels. For example, the total nitrosamines were reported to be in the range of 1.6–62.4 ng/L. | (Wang et al. |
aMethicillin-resistant Staphylococcus aureus
Fig. 2Overview of possible fate and transport of CBDs during and after application
Classes of DBPs, individual chemical composition, and human health risk indices
| DBPs | Chemical composition | Regulatory guidelinesa | Health risk indicesb | |||
|---|---|---|---|---|---|---|
| WHO | USEPA | Genotoxicity | Carcinogenicity | Cancer probability and critical organ (tumor site)c | ||
| Trichloromethane (chloroform) | CHCl3 | 300 µg/L | 80 µg/L for total THMs | − | + | B2. Hepatic (hepatic) |
| Bromodichloromethane | CHBrCl2 | 60 µg/L | + | + | B2. Urinary (urinary) | |
| Dibromochloromethane | CHBr2Cl | 100 µg/L | + | + | C. Hepatic (hepatic) | |
| Tribromomethane (bromoform) | CHBr3 | 100 µg/L | + | + | B2. Hepatic (gastrointestinal) | |
| Chloroacetic acid | CH2ClCOOH | 60 µg/L for total of HHA5 | + | − | ||
| Bromoacetic acid | CH2BrCOOH | + | ||||
| Dichloroacetic acid | CHCl2COOH | 50 µg/L | + | + | Likely to be carcinogenic. Hepatic, nervous, and reproductive (hepatic). | |
| Dibromoacetic acid | CHBr2COOH | + | + | |||
| Trichloracetic acid | CCl3COOH | 100 µg/L | + | Suggestive evidence of carcinogenic potential. Hepatic (hepatic). | ||
| Bromodichloroacetic acid | CBrCl2OOH | + | ||||
| Dibromochloroacetic acid | CBr2ClOOH | + | ||||
| Bromochloroacetic acid | CHBrClCOOH | - | + | |||
| Tribromoacetic acid | CBr3COOH | + | ||||
| Chloroacetonitrile | CH2ClCN | + | ||||
| Bromoacetonitrile | CH2BrCN | + | ||||
| Dichloroacetonitrile | CHCl2CN | 90 µg/L | + | |||
| Dibromoacetonitrile | CHBr2CN | 100 µg/L | + | |||
| Bromochloroacetonitrile | CHBrClCN | + | ||||
| Bromodichloroacetonitrile | CBrCl2CN | |||||
| Dibromochloroacetonitrile | CBr2ClCN | |||||
| Trichloroacetonitrile | CCl3CN | 1 µg/L | + | |||
| Tribromoacetonitrile | CBr3CN | |||||
| Formaldehyde | CH2O | 900 µg/L | + | + | B1. Gastrointestinal and urinary (respiratory). | |
| Acetaldehyde | CH3CHO | + | + | B2. Nervous and respiratory (respiratory). | ||
| Chloroacetaldehydes | CH2ClCHO | + | ||||
| Bromoacetaldehydes | CH2BrCHO | |||||
| Dichloroacetaldehydes | CHCl2CHO | |||||
| Dibromoacetaldehyde | CHBr2CHO | |||||
| Bromochloroacetaldehyde | CHBrClCHO | |||||
| Bromodichloroacetaldehyde | CBrCl2CHO | |||||
| Dibromochloroacetaldehyde | CBr2ClCHO | |||||
| Trichloroacetaldehyde (chloral hydrate) | CCl3CH(OH)2d | 10 µg/L | + | + | C. Gastrointestinal and nervous. | |
| Tribromoacetaldehyde | CBr3CHO | |||||
| 1,1-Dichloroacetone | CHCl2COCH3 | + | ||||
| 1,1,1-Trichloroacetone | CCl3COCH3 | + | ||||
| Dichloroiodomethane | CHCl2I | |||||
| Dibromoiodomethane | CHBr2I | |||||
| Chlorodiiodomethane | CHClI2 | |||||
| Bromodiiodomethane | CHBrI2 | |||||
| Bromochloroiodomethane | CHBrClI | |||||
| Iodoform | CHI3 | + | ||||
| Iodoacetic acid | CH2ICOOH | + | ||||
| Bromoiodoacetic acid | CHBrICOOH | + | ||||
| Iodoacetonitrile | CH2ICN | + | ||||
| Chloroacetamide | CH2ClCONH2 | + | ||||
| Bromoacetamide | CH2BrCONH2 | + | ||||
| Iodoacetamide | CH2ICONH2 | + | ||||
| Dichloroacetamide | CHCl2CONH2 | + | ||||
| Dibromoacetamide | CHBr2CONH2 | + | ||||
| Diiodoacetamide | CHI2CONH2 | + | ||||
| Bromochloroacetamide | CHBrClCONH2 | + | ||||
| Bromoiodoacetamide | CHBrICONH2 | + | ||||
| Chloroiodoacetamide | CHClICONH2 | + | ||||
| Bromodichloroacetamide | CBrCl2CONH2 | + | ||||
| Dibromochloroacetamide | CBr2ClCONH2 | + | ||||
| Trichloroacetamide | CCl3CONH2 | + | ||||
| Tribromoacetamide | CBr3CONH2 | + | ||||
| N-Nitrsodimethylamine (NDMA) | (CH3)2-N(NO) | + | + | B2. (Hepatic) | ||
| N-Nitrosopyrrolidine (NPYR) | C4H8-N(NO) | + | + | B2. (Hepatic) | ||
| N-Nitrosomorpholine (NMOR) | C4H8N2O2 | + | + | |||
| N-Nitrosopiperidine (NPIP) | C5H10-N(NO) | + | + | |||
| N-Nitrosodiphenylamine | C12H10N2O | + | + | B2. (Urinary) | ||
| N-Nitrosomethylethylamine | (CH3)C2H5-N(NO) | + | + | B2. (Hepatic) | ||
| N-Nitrosodiethylamin | (C2H5)2-N(NO) | + | + | B2. (Hepatic) | ||
aMaximum concentration allowed in drinking water; compounds unregulated are left as blank cells.
b+indicates positive evidence, − indicates negative evidence, and blank cell indicates lack of data.
cLetters denote weight of evidence classes as B1: probable human carcinogen based on limited evidence of carcinogenicity in humans, B2: probable human carcinogen based on sufficient evidence of carcinogenicity in animals, C: possible human carcinogen; human physiological system that is at risk to a particular compound, and possible tumor site is given in bracket—adopted from USEPA IRIS database.
dChemical formula of chloral hydrate
Guidelines from various agencies regarding the use of CBDs for hospital disinfection during the COVID-19 pandemic
| Health agency | Suggested disinfection measures for healthcare settings and norms for environmental cleaning |
|---|---|
| World Health Organization | |
| Department of Health, Australian Government | Freshly made bleach solution of appropriate concentration is to be used to disinfect patient, and non-patient areas. In-patient areas should be frequently disinfected. Equipment should be cleaned and decontaminated after each use. Terminal cleaning of a room should be carried out when a patient is discharged or vacated. A 2-in-1 process, where a combined detergent and hospital grade disinfectant or sodium hypochlorite, or a 2-step process, where physical cleaning with detergent followed by sodium hypochlorite/hospital grade disinfectant is to be used. |
| Chinese Center for Disease Control and Prevention | Disinfection of commonly contaminated objects in a medical institution/quarantine center/household where an infected person resided. |
| Health Department, Republic of South Africa | For environmental cleaning frequent cleaning of 2–3 times (3–4 times in high-risk areas) per day followed by wiping with disinfectant containing 1000 ppm available chlorine or 70% alcohol is advised. Liquid and solid hypochlorite, chloramine, NaDCC tablets, or powder are recommended for disinfection. The predicted amount of 0.5% hypochlorite solution for a single healthcare worker is 10 L and 15 L in COVID-19 ward and ICU respectively. |
| Public Health Department, Government of UK |
DBPs formed by chlorination of pharmaceutical/medical products and their toxicity. (Reference: (Wang et al. 2020a, b), (Negreira et al. 2016; 2015a,b,c), (Romanucci et al. 2019), (Duirk et al. 2011))
| Compounds that formed DBPs with chlorine | Reaction media used in the study | DBP analogues detected | Status of toxicity assaya |
|---|---|---|---|
Antibiotics i. Ciprofloxacin ii. Sulfamerazine iii. Chloramphenicol | Milli-Q water | THMs, HAAs (BCAA, TCAA, DCAA, MBAA, and MCAA), HKs, HANs, and TCNM | + |
Anti-cancer drugs i. Etoposide | River water, WWTP influent, and effluent | By-product 1 and 2b (BP1: C28H29O13−, BP2: C26H25O13−) | − |
| ii. Tamoxifen (TAM) | Ultra-pure water and wastewater | OH-TAMc DBPs: DBP-438: C26H28O3NCl, DBP-472: C26H27O3NCl2, DBP-422A: C26H28O2NCl, DBP-422B: C26H28O2NCl, DBP-456: C26H27O2NCl2, DBP-440: C25H23O2NCl2, and DBP-454: C26H25O2NCl2 OH-D-TAMc DBP: DBP-424: C25H26O3NCl, DBP-458A: C25H25O3NCl2, DBP-458B: C25H25O3NCl2, DBP-458C: C25H25O3NCl2, DBP-408: C25H26O2NCl, DBP-442; C25H25O2NCl2, and DBP-440; C25H23O2NCl2 | + |
| iii. Erlotinibd | Ultra-pure water and wastewater | TP-444: C22H22O5N3Cl, TP-428A: C22H22O4N3Cl, TP-428B: C22H22O4N3Cl, TP-428C: C22H22O4N3Cl, TP-462A: C22H21O4N3Cl2, and TP-462B: C22H21O4N3Cl2 | − |
iv. Vinca alkaloids: vincristine, vinblastine, vinorelbine, and deacetyl vinorelbyne | Ultra-pure water and wastewater | Total of sixty-five by-products were formed including twenty mono, 8 di-, and 2 tri-chlorinated compounds. | − |
| Tramadol (TRA) | Milli-Q water | BP1: C16H24ClNO2, BP2: C14H21NO3, BP3: C14H18O3, BP4: C16H23NO2, BP5: C17H23ClO5, BP6: C16H23NO3, and BP7: C15H20N2O3 | + |
| Iodinated contrast media (ICM); iopamidol, iohexol, and iopromide | Purified water and river watere | Iodo-THMS: dichloroiodomethane, dibromoiodomethane, chlorodiiodomethane, bromochloroiodomethane, bromodiiodomethane, and iodoform. Iodo-acids: iodoacetic acid, bromoiodoacetic acid, (Z)-3-bromo-3-iodopropenoic acid, (E)-3-bromo-3-iodopropenoic acid, and (E)-2-iodo-3-methylbutenedioic acid. | Iodo-THMs + iodo-acids + |
a+ indicates toxicity assessment has been done in the respective study and the by-products were found to be toxic, − indicates toxicity assessment has not been carried out in the respective study.
bProposed chemical formula.
cDBPs were formed from metabolites of TAM.
dOut of total 19 products formed, only chlorinated ones are listed.
eIohexol and iopromide generated I-DBPs only in purified water.
Fig. 3Ozone destruction cycle of chlorine. The chlorine catalytic cycle involves the cyclic formation of Cl atom and ClO and subsequent destruction of the ozone layer